MwanzoEVGN • NASDAQ
add
Evogene Ltd
$ 1.76
Baada ya Saa za Kazi:(0.57%)+0.0100
$ 1.77
Imefungwa: 8 Nov, 18:55:21 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 1.80
Bei za siku
$ 1.70 - $ 1.83
Bei za mwaka
$ 1.70 - $ 10.40
Thamani ya kampuni katika soko
8.90M USD
Wastani wa hisa zilizouzwa
elfu 527.92
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 914.00 | 39.76% |
Matumizi ya uendeshaji wa biashara | 6.47M | -20.01% |
Mapato halisi | -5.42M | 22.84% |
Kiwango cha faida halisi | -592.89 | 44.79% |
Mapato kwa kila hisa | -1.06 | 37.65% |
EBITDA | -5.48M | 24.40% |
Asilimia ya kodi ya mapato | -0.02% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 20.91M | -38.28% |
Jumla ya mali | 40.97M | -23.19% |
Jumla ya dhima | 21.03M | -5.41% |
Jumla ya hisa | 19.94M | — |
hisa zilizosalia | 5.10M | — |
Uwiano wa bei na thamani | 3.00 | — |
Faida inayotokana na mali | -34.74% | — |
Faida inayotokana mtaji | -64.68% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -5.42M | 22.84% |
Pesa kutokana na shughuli | -5.46M | -7.15% |
Pesa kutokana na uwekezaji | 3.21M | 140.63% |
Pesa kutokana na ufadhili | elfu -151.00 | -101.45% |
Mabadiliko halisi ya pesa taslimu | -2.43M | 12.14% |
Mtiririko huru wa pesa | 7.01M | 458.53% |
Kuhusu
Evogene is a computational biology company based in Israel. Evogene Ltd. has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence, while adding a deep understanding of biology and advanced biological technologies. Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF, Bayer, Corteva, ICL Group Ltd. as well as various academic and medical institutions. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2002
Tovuti
Wafanyakazi
142
